Advanced search
Start date

Development of a nanomicelle for carrying the MT29 molecule for the treatment of cancer-induced cachexia

Grant number: 22/05884-3
Support Opportunities:Research Grants - Innovative Research in Small Business - PIPE
Duration: September 01, 2022 - August 31, 2024
Field of knowledge:Biological Sciences - Biology
Principal Investigator:Milena Trevisan Pelegrino
Grantee:Milena Trevisan Pelegrino
Host Company:Mirscience Therapeutics Serviços de Pesquisa e Desenvolvimento Ltda
CNAE: Pesquisa e desenvolvimento experimental em ciências físicas e naturais
Atividades de ensino não especificadas anteriormente
City: São Paulo
Associated researchers: Lucas Ariel Fernandes da Rocha ; Vinicius Ramos Henriques Maracajá Coutinho
Associated research grant:21/06754-3 - Development of the miR-29c (miR-MT29) for the treatment of skeletal muscle atrophy, AP.PIPE
Associated scholarship(s):22/10692-6 - Development of the MT29 molecule for the treatment of cancer-induced cachexia, BP.TT


Conserving the quality of muscle tissue is a key factor for a healthier and longer life. Muscle atrophy is an adaptive process that reduces muscle mass and function in several cases, such as cachexia in cancer and sarcopenia in aging, directly affecting quality of life and increasing mortality. In a recent work, we demonstrated that the overexpression of miR-29c microRNA is capable of increasing skeletal muscle mass and function in mice and reducing genes related to muscle atrophy in vitro and in vivo. Furthermore, in our PIPE phase 1 project, we demonstrated that miR-29c was also able to inhibit muscle atrophy in cachectic mice. To advance our program, focusing on future clinical studies, in our PIPE phase 2 project (linked project), we built a new oligonucleotide based on this microRNA, called MT29. MT29 is under development in the PIPE 2 project, where its chemical structure has been modified and its therapeutic dose analyzed in muscle atrophy models, however, to improve its efficiency, we need its delivery (drug delivery) to be specific to the skeletal muscle, with a reduction of off-target effects and lower dose. Thus, in this PIPE invest proposal, our main objective is to improve our MT29 technology, through the construction of an efficient and specific carrying system for skeletal muscle and for the treatment of cancer-induced cachexia, in line with the objectives and results of PIPE phase 2. In the first phase of PIPE invest, we developed specific nanomicelles for the muscle and we will test two types of compositions in vitro, analyzing their efficiency and cell uptake. In the second phase, we will optimize the use in vivo, optimizing the dose, response and therapeutic effect in mice with cancer-induced cachexia. At the end of this PIPE invest project, we will be ready for the development of IND (investigational new drug) pre-clinical studies, and with that, we will have a very important advance in the development of a disruptive product with global potential in the area of precision medicine. (AU)

Articles published in Agência FAPESP Newsletter about the research grant:
Articles published in other media outlets (0 total):
More itemsLess items

Please report errors in scientific publications list by writing to: